BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6153747)

  • 1. Resistance system of Mycobacterium bovis B.C.B. to aminoglycoside- and peptide-antibiotics. Comparison of resistant phenotypes between Mycobacterium tuberculosis and Mycobacterium bovis.
    Tsukamura M
    Microbiol Immunol; 1980; 24(1):11-9. PubMed ID: 6153747
    [No Abstract]   [Full Text] [Related]  

  • 2. Cross-resistant relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis.
    Tsukamura M; Mizuno S
    J Gen Microbiol; 1975 Jun; 88(2):269-74. PubMed ID: 50402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antimycobacterial activity of capreomycin.
    Lucchesi M
    Antibiot Chemother; 1970; 16():27-31. PubMed ID: 4108891
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cross-resistance of tubercle bacilli (a review) (III) (author's transl)].
    Tsukamura M
    Kekkaku; 1977 Apr; 52(4):171-5. PubMed ID: 69737
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cross resistance of tubercle bacilli to KM, VM, CPM, LVM and TUM. I. The sensitivity of human tubercle bacilli isolated from patients to the five antibiotics (author's transl)].
    Saito T; Fukuhara Y
    Kekkaku; 1974 Mar; 49(3):57-61. PubMed ID: 4136031
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug resistance of tubercle bacilli -- from the clinical point of view (author's transl)].
    Fukuhara Y
    Kekkaku; 1976 Dec; 51(12):477-87. PubMed ID: 65494
    [No Abstract]   [Full Text] [Related]  

  • 7. [Susceptibility of drug-resistant tubercle bacilli isolated from pulmonary tuberculosis in patients to paromomycin (Aminosidine) (author's transl)].
    Endo K
    Jpn J Antibiot; 1974 Apr; 27(2):141-3. PubMed ID: 4136451
    [No Abstract]   [Full Text] [Related]  

  • 8. [Critical concentrations for resistances of tubercle bacilli to tuberactinomycin-N, viomycin, capreomycin, and lividomycin in patients treated with these agents (cross-resistance-relationships among resistances to aminoglucoside-antibiotics found during chemotherapy for tuberculosis) (author's transl)].
    Tsukamura M; Mizuno S; Murata H; Oshima T
    Kekkaku; 1975 May; 50(4-5):123-30. PubMed ID: 49449
    [No Abstract]   [Full Text] [Related]  

  • 9. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin.
    McClatchy JK; Kanes W; Davidson PT; Moulding TS
    Tubercle; 1977 Mar; 58(1):29-34. PubMed ID: 68613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cross-resistance relationship among capreomycin, kanamycin, viomycin and streptomycin resistance of Mycobacterium tuberculosis].
    Tsukamura M; Toyama H; Mizuno S; Tsukamura S
    Kekkaku; 1967 Oct; 42(10):399-404. PubMed ID: 4295935
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evaluation of kanamycin, viomycin and capreomycin resistance of Mycobacterium tuberculosis].
    Tomoda T; Minami Y; Maekawa Y; Oi Y
    Rinsho Byori; 1971 Jun; 19(6):423-6. PubMed ID: 4111341
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effects of streptomycin-resistance of Mycobacterium tuberculosis on induction rate of resistance to kanamycin, viomycin and capreomycin and on cross-resistance among these drugs].
    Nagata A; Mase M; Yamamoto M; Nakamura H
    Kekkaku; 1969 Jun; 44(6):173-9. PubMed ID: 4308767
    [No Abstract]   [Full Text] [Related]  

  • 13. [The degree of cross-resistance to kanamycin (KM) of tubercle bacilli resistant to capreomycin (CPM), and the degree of cross-resistance to KM and CPM of tubercle bacilli resistant to viomycin (VM) (author's transl)].
    Inagake H; Yamadori H; Inoue N; Mabuchi H; Ikeda N; Maekawa N
    Kekkaku; 1980 Jul; 55(7):323-30. PubMed ID: 6162994
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on lividomycin. I. In vitro antibacterial activities of LVDM against clinical isolates of Mycobacterium tuberculosis.
    Shimizu T
    Jpn J Antibiot; 1974 Dec; 27(6):766-74. PubMed ID: 4142798
    [No Abstract]   [Full Text] [Related]  

  • 15. [Activities of rifampicin, capreomycin, viomycin or kanamycin against Mycobacterium tuberculosis isolated from tuberculosis patients].
    Endo K
    Jpn J Antibiot; 1970 Aug; 23(4):387-9. PubMed ID: 4321638
    [No Abstract]   [Full Text] [Related]  

  • 16. Investigation into the relationship of M ulcerans to M. buruli and other mycobacteria.
    Schröder KH
    Am Rev Respir Dis; 1975 Apr; 111(4):559-62. PubMed ID: 47730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-resistance relationships between capreomycin, kanamycin, and viomycin resistances in tubecle bacilli from paients.
    Tsukamura M
    Am Rev Respir Dis; 1969 May; 99(5):780-2. PubMed ID: 4306213
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cross resistance of tubercle bacilli to KM, VM, CPM, LVM, and TUM. II. The susceptibility of antibiotic-resistant strains which were obtained in vitro to the five antibiotics (author's transl)].
    Saito T; Fukuhara Y
    Kekkaku; 1974 Apr; 49(4):91-6. PubMed ID: 4137393
    [No Abstract]   [Full Text] [Related]  

  • 19. [In vitro antituberculous activity of lividomycin].
    Kobayashi F; Nagoya T; Eda J; Yoshimura Y
    Jpn J Antibiot; 1972 Dec; 25(6):360-6. PubMed ID: 4125073
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
    Maus CE; Plikaytis BB; Shinnick TM
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.